By Gail Dutton OnQuality Pharmaceuticals just raised $20 million in Series A+ funding to support its Phase II oncodermatology trial. The trial assesses the safety and efficacy of a targeted supportive care agent that addresses the specific side effects of vascular endothelial growth factor receptor (VEGFR) inhibitors among cancer patients. Read more here: https://www.biospace.com/article/onquality-pharma-raises-20-million-to-support-ongoing-oncodermatology-trials/?s=81
top of page
bottom of page